Every Form 4 that Halozyme Therapeutics, Inc. (HALO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HALO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HALO filings page.
HALOZYME THERAPEUTICS, INC. (HALO) director Matthew L. Posard reported selling a total of 18,996 shares of common stock on September 16, 2026 in four open-market transactions. The sales, at weighted average prices between about $106 and $109 per share, were made under a Rule 10b5-1 trading plan adopted June 15, 2026.
HALOZYME THERAPEUTICS, INC. (HALO) reported that President and CEO Helen Torley exercised stock options for 60,000 shares of common stock at an exercise price of $18.41 per share over September 9–11, 2026, and sold 60,000 shares at weighted average prices around $107 per share under a pre-arranged Rule 10b5-1 trading plan.
HALOZYME THERAPEUTICS, INC. (HALO) reported that director Dannielle Appelhans received equity-based compensation on September 1, 2026. She was granted 1,161 Restricted Stock Units, each representing one common share, and options to purchase 1,778 shares of common stock at an exercise price of $107.72 per share. Both the RSUs and the stock options are scheduled to vest in full on the date of Halozyme’s 2027 annual meeting of stockholders. No Rule 10b5-1 trading plan is reported for these awards.
HALOZYME THERAPEUTICS, INC. (HALO) reported that President and CEO Helen Torley exercised stock options and sold common shares under a pre-arranged Rule 10b5-1 trading plan. Over August 17–19, 2026, she exercised options for 60,000 shares at $18.41 per share and sold 60,000 common shares in multiple open-market transactions at weighted-average prices generally between the high $90s and about $108 per share. The options exercised were part of a ten-year grant originally awarded in February 2018 and expiring in February 2028.
HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton reported a sale of 1,626 shares of common stock on 2026-08-10 at $102.80 per share. After this transaction, she directly holds 40,418 shares. The sale was made under a Rule 10b5-1 written trading plan adopted on May 29, 2025.
Halozyme Therapeutics President and CEO Helen Torley exercised stock options for 1,923 shares of common stock at $12.07 per share and immediately sold the same 1,923 shares in open‑market transactions at prices around $79–$80 per share. These trades were carried out under a pre‑arranged Rule 10b5-1 trading plan adopted on March 21, 2025, and involved options that were due to expire in February 2027. After these transactions, Torley directly holds 767,780 shares of Halozyme common stock.
HALOZYME THERAPEUTICS EVP David A. Ramsay reported a series of equity compensation transactions. On July 1, 2026 he received an option to buy 39,823 shares of common stock at $77.01 per share and a grant of 16,232 restricted stock units.
On June 30, 2026 10,000 restricted stock units vested and were settled in common shares, with 5,408 shares withheld by the company to cover tax obligations and 4,592 shares remaining directly owned. The filing shows routine grants, vesting, and tax withholding rather than open-market trading.
HALOZYME THERAPEUTICS, INC. reported that SVP and Chief Financial Officer Darren Snellgrove received new equity awards on July 1, 2026. He was granted options to purchase 127,432 shares of common stock at an exercise price of $77.01 per share, along with 41,554 restricted stock units (RSUs).
The options begin vesting one-fourth on the first vesting date and then in equal monthly installments over 48 months, while the RSUs vest in three equal annual installments starting on the first anniversary of the grant date. These are compensation-related grants, not open‑market purchases or sales, and increase the CFO’s potential future ownership if vesting and exercise conditions are met.
HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton reported open-market sales of a total of 1,625 shares of common stock. The trades were executed at weighted average prices of about $76 to $77 per share across two price ranges.
The sales were made under a pre-arranged written trading plan adopted on May 29, 2025 in accordance with Rule 10b5-1, indicating these transactions were scheduled in advance as part of ongoing portfolio management rather than discretionary timing decisions.
HALOZYME THERAPEUTICS, INC. director Mahesh Krishnan reported an exercise-and-sale transaction in company stock. He exercised options to acquire 7,304 shares of common stock at $38.46 per share, then sold 7,304 shares in an open-market transaction at $75.00 per share.
After these transactions, he holds 14,462 common shares directly and 1,500 options to purchase common stock. The filing states the option exercise and related sale were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 19, 2026, indicating the timing was set in advance.
HALOZYME THERAPEUTICS, INC. executive Mark Howard Snyder reported routine equity compensation activity involving restricted stock units. On June 12, 5,034 restricted stock units converted into the same number of common shares. The company withheld 2,715 shares at a market price of $69.50 per share to cover tax obligations, which was recorded as a disposition but not an open‑market sale. Following these transactions, Snyder directly owned 49,929 shares of common stock. The filing shows no open‑market buying or selling, only vesting, conversion, and tax withholding mechanics typical of executive compensation.
HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley reported a series of insider trades in early June 2026. She sold 50,000 shares of common stock in open-market transactions at prices in the mid-to-high $60s per share, according to the Form 4 data.
On the same dates, she exercised 50,000 stock options with an exercise price of $12.07 per share that were due to expire in February 2027. After these transactions, she directly holds 767,780 shares of Halozyme common stock and retains 1,923 options with a $12.07 exercise price expiring in 2027.
The footnotes state that the option exercises and related sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 21, 2025, indicating the timing of these trades was set in advance.
HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton reported an open-market sale of common stock. On June 1, 2026, she sold 1,625 shares at an average price of $66.21 per share. After this transaction, she holds 43,669 shares of Halozyme common stock directly.
The footnotes state that these sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 29, 2025, indicating the trades were scheduled in advance rather than timed discretionarily.
HALOZYME THERAPEUTICS, INC. CEO Helen Torley reported a series of option exercises and related share sales in May. Over May 11–13, she exercised options to acquire 50,000 shares of common stock at $12.07 per share and sold 50,000 shares in open-market trades at prices generally in the mid‑$60s to low‑$70s per share. The filing notes these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 21, 2025 and that the sales relate to options with a ten-year term expiring in February 2027. Following the reported transactions, she directly holds 767,780 shares of common stock and retains vested options to purchase 51,923 shares.
HALOZYME THERAPEUTICS, INC. director Matthew L. Posard received equity awards as part of the company’s director compensation program. He was granted 3,796 restricted stock units, each representing one future share of common stock, and options for 6,040 shares at an exercise price of $65.87 per share.
The RSUs and options vest in full on the earlier of May 5, 2027 or the next annual meeting of stockholders. The RSUs are subject to a deferral election so shares are delivered when he completes his service as a director. After these grants, he directly holds 77,835 common shares.
HALOZYME THERAPEUTICS, INC. director Mahesh Krishnan received equity awards consisting of common stock and stock options as part of the company’s director compensation program. He acquired 3,796 shares of common stock at no cash cost through a restricted stock unit grant.
He was also granted options to purchase 6,040 shares of common stock at an exercise price of $65.87 per share, expiring on May 5, 2036. Both the RSUs and options vest in full on the earlier of May 5, 2027 or the company’s next annual meeting of stockholders. After these grants, he directly holds 14,462 shares of common stock.
Halozyme Therapeutics director James Paul Lang received equity awards as part of the company’s director compensation program. He was granted 3,796 restricted stock units, each representing one share of common stock, bringing his direct common stock holdings to 4,685 shares.
Lang also received options to purchase 6,040 shares of common stock at an exercise price of $65.87 per share, expiring on May 5, 2036. Both the RSUs and options vest in full on the earlier of May 5, 2027 or the next annual stockholder meeting, with RSU settlement deferred until completion of his board service.
Henderson Jeffrey William reported acquisition or exercise transactions in this Form 4 filing.
HALOZYME THERAPEUTICS director Jeffrey William Henderson received equity compensation in the form of stock and options. He was granted 3,796 restricted stock units, each representing one share of common stock, and an option to purchase 6,040 shares at $65.87 per share.
The RSU and stock option grants are part of the company’s director compensation program. Both awards vest in full on the earlier of May 5, 2027 or the date of the company’s next annual meeting of stockholders. Following the grants, he directly holds 36,572 shares of common stock.
HALOZYME THERAPEUTICS, INC. director Barbara Gayle Duncan received equity compensation in the form of restricted stock units and stock options. She was granted 3,796 shares of common stock as annual RSUs and an option for 6,040 shares of common stock.
The RSUs and options are part of the issuer's director compensation program and each RSU represents one share of common stock. Both awards vest in full on the earlier of May 5, 2027 or the date of the next annual meeting of stockholders. Following the RSU grant, she holds 23,715 common shares directly, and the new option has an exercise price of $65.87 per share and expires on May 5, 2036.
HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton received equity compensation awards on May 5, 2026. She was granted 6,796 restricted stock units (RSUs), each representing one share of common stock, and a stock option for 6,040 shares at an exercise price of $65.87 per share.
Both the RSU grant and the option grant will vest in full on the earlier of May 5, 2027 or the date of the company’s next annual meeting of stockholders. Following the RSU award, Connaughton directly holds 45,294 shares of common stock.
HALOZYME THERAPEUTICS, INC. director Bernadette Connaughton sold 1,625 shares of common stock in an open-market transaction at $63.48 per share. After this sale, she directly holds 38,498 shares. The filing notes the sale was made under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance.
HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley exercised stock options for 10,000 shares of common stock at an exercise price of $12.070 per share on April 6, 2026. The options were part of a grant dated February 22, 2017 with a ten-year term.
On the same date, she sold a total of 10,000 common shares in open-market transactions at weighted average prices of $63.139 and $64.015 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, she directly holds 767,780 common shares.
RAMSAY DAVID A reported acquisition or exercise transactions in this Form 4 filing.
HALOZYME THERAPEUTICS, INC. reported that interim CFO David A. Ramsay received a grant of 10,000 Restricted Stock Units tied to the company’s common stock. These RSUs were awarded as compensation rather than through an open-market purchase or sale.
The award vests in full on June 30, 2026, provided he remains employed through that date. After vesting, the shares are subject to a one-year holding period, meaning he must continue to hold the resulting shares for an additional year. Following this grant, his directly held RSU-related position from this award is 10,000 units.
HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley reported an exercise-and-sell transaction in company stock. On April 1–2, she exercised options to acquire a total of 40,000 shares of common stock at an exercise price of $12.0700 per share, from options with a ten-year term expiring in February 2027.
Over the same two days, she sold 40,000 shares of common stock in open-market trades at per-share prices including $65.3580, $65.7140, $64.0630 and $64.8870. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. After the transactions, she directly owned 767,780 shares of Halozyme common stock.
HALOZYME THERAPEUTICS, INC. senior vice president and chief operating officer Cortney Caudill reported an exercise-and-sell transaction in company stock. On March 9–10, 2026, she exercised options to acquire a total of 21,546 shares of common stock at an exercise price of $33.51 per share.
Over the same two days, she conducted open-market sales totaling 28,857 shares of common stock at weighted average prices around $67.64–$68.25, with specific trades executed in price ranges disclosed in the footnotes. Following these transactions, she directly holds 7,055 shares of common stock and retains 67,678 options to purchase common stock.
HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley reported a combination of option exercises and share sales. Over March 2–4, 2026, she exercised options to acquire 50,000 shares of common stock at an exercise price of $12.07 per share.
She then sold 50,000 shares of common stock in multiple open‑market transactions under a pre‑established Rule 10b5‑1 trading plan, at weighted average prices within ranges between $68.22 and $71.36 per share. After these transactions, she directly owned 767,780 common shares.
HALOZYME THERAPEUTICS, INC. senior vice president and chief operating officer Cortney Caudill reported routine equity award activity. On February 20, 2026, 2,666 Restricted Stock Units vested and were settled into 2,666 shares of common stock, reflecting an exercise or conversion of derivative securities at a stated price of $0.0000 per share.
To cover tax withholding obligations from this vesting, 1,037 common shares were automatically withheld by the issuer at a price of $70.98 per share, as noted in the footnotes. After these transactions, Caudill directly owned 14,366 shares of common stock and 7,998 Restricted Stock Units. These movements reflect compensation-related settlements and tax withholding rather than open-market buying or selling.
Halozyme Therapeutics SVP and Chief Legal Officer Mark Howard Snyder reported multiple equity compensation events. On February 20 and 23, 2026, restricted stock units vested and were settled into 5,332 and 7,011 shares of common stock, respectively, through derivative exercises at $0.00 per share.
To satisfy tax withholding obligations, the issuer withheld 2,876 shares at $70.98 and 3,782 shares at $70.64, recorded as tax-withholding dispositions rather than open-market sales. After these transactions, Snyder directly owned 47,610 shares of Halozyme common stock.
Halozyme Therapeutics SVP & CFO Nicole LaBrosse reported equity award vesting and related tax-withholding transactions. On February 23, 6,688 Performance Stock Units were exercised into 6,688 shares of common stock, and 3,608 shares were withheld at $70.64 per share to cover taxes. On February 20, 5,332 Restricted Stock Units vested into 5,332 common shares, with 2,876 shares withheld at $70.98 per share for tax obligations. After these transactions, she directly held 38,494 shares of common stock, 36,357 Performance Stock Units, and 15,995 Restricted Stock Units.
HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley reported equity compensation activity involving restricted stock units and related common stock. On February 20 and 23, 2026, restricted stock units vested and were settled into a total of 22436 and 16757 shares of common stock through derivative exercises.
On both dates, a portion of the newly delivered common shares, 9040 and 12104 shares respectively, was automatically withheld by the issuer to cover tax withholding obligations at prices of $70.98 and $70.64 per share, rather than sold in open‑market transactions. After these transactions, Torley directly owned 767780 shares of common stock and 44872 restricted stock units.
Snyder Mark Howard reported multiple insider transaction types in a Form 4 filing for HALO. The filing lists transactions totaling 42,692 shares at a weighted average price of $79.44 per share. Following the reported transactions, holdings were 4,796 shares.
LaBrosse Nicole reported multiple insider transaction types in a Form 4 filing for HALO. The filing lists transactions totaling 60,440 shares at a weighted average price of $79.44 per share. Following the reported transactions, holdings were 5,329 shares.
Torley Helen reported multiple insider transaction types in a Form 4 filing for HALO. The filing lists transactions totaling 226,153 shares at a weighted average price of $79.44 per share. Following the reported transactions, holdings were 16,874 shares.
Halozyme Therapeutics executive Cortney Caudill received new equity awards under the company’s compensation programs. On 02/09/2026, the SVP and Chief Operating Officer acquired an option to purchase 14,047 shares of common stock at $80.48 per share, vesting over four years starting 02/09/2027.
Caudill was also granted 13,047 restricted stock units that vest 25% on the first anniversary of the grant date and 25% on each anniversary thereafter. In addition, performance stock units tied to performance periods ending December 31, 2025 became eligible to vest, covering 2,403 and 14,751 shares, subject to continued service through the third anniversary of their original PSU grant dates.
Halozyme Therapeutics reported that SVP and Chief Legal Officer Mark Howard Snyder received several equity awards on February 9, 2026. He was granted an option to purchase 18,730 shares of common stock at an exercise price of $80.48, vesting one-fourth on the grant date and then monthly in equal installments.
He was also awarded 17,396 restricted stock units that vest in four equal annual installments starting one year after the grant, plus multiple performance stock unit awards. Performance stock units of 4,651, 7,808, and 29,502 shares became eligible to vest based on a performance period ending December 31, 2025 and remain subject to additional service-based vesting through the third anniversary of each original PSU grant date.
Halozyme Therapeutics executive Nicole LaBrosse, SVP and Chief Financial Officer, reported new equity awards tied to prior performance-based grants. On February 9, 2026, she acquired 5,167, 7,448, and 29,502 performance stock units at $0 per unit, each representing a contingent right to one share of common stock.
The units reflect the company’s determination of how many stock units became eligible to vest based on performance periods ending December 31, 2025 for PSU awards originally granted in 2023, 2024, and 2025. These awards remain subject to continued service through the third anniversary of each original grant date.
Halozyme Therapeutics President and CEO Helen Torley, who is also a director, reported receiving new equity awards on February 9, 2026. She was granted an option to purchase 53,847 shares of common stock at an exercise price of $80.48 per share.
Torley also acquired 50,013 restricted stock units, plus multiple performance stock unit (PSU) awards of 19,807, 24,985, and 92,714 units. These PSUs became eligible to vest based on a performance period ending December 31, 2025 and remain subject to ongoing service-based vesting, generally through the third anniversary of each PSU grant date.
Halozyme Therapeutics, Inc. President and CEO Helen Torley, who is also a director, reported a series of option exercises and related stock sales in early February 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on March 21, 2025.
On February 3–5, 2026, she exercised company stock options at an exercise price of $12.07 per share and sold the resulting common shares in multiple transactions at weighted average prices generally in the mid-to-high $70s per share, as detailed in the price ranges disclosed for each trade.
Following these transactions, she directly held 708,719 shares of Halozyme common stock and 201,923 options to purchase common stock, with the options originally granted on February 22, 2017 and exercisable over a four-year vesting schedule.
Halozyme Therapeutics (HALO) insider activity: The President and CEO, who also serves as a director, exercised stock options and sold shares under a Rule 10b5-1 trading plan adopted on March 21, 2025.
Across November 10–12, 2025, the executive exercised 60,000 options at $8.11 per share (20,000 each day) and sold 60,000 shares in multiple tranches. Reported weighted average sales prices included $68.714 and $69.3 on November 10; $67.892, $68.795, and $69.731 on November 11; and $70.218, $71.089, and $71.667 on November 12. The sales reflect shares acquired from option exercises, with the underlying options having a ten‑year term expiring in February 2026.
Following the reported transactions, the executive beneficially owned 733,719 shares directly. Remaining options beneficially owned declined to 16,569 after these exercises.
Halozyme Therapeutics (HALO) reported an insider transaction by a director. On 11/10/2025, the director sold 2,000 shares of common stock at $68.48 per share under a Rule 10b5-1 trading plan adopted on May 29, 2025. Following the sale, the director beneficially owns 42,952 shares, held directly.
Officer equity grants and option exercise reported. The reporting person, Cortney Caudill, SVP and Chief Operating Officer, acquired 9,031 shares via an option exercise with an exercise price of $68.98 and was granted 3,625 restricted stock units (RSUs). The option vests 25% on 10/03/2026 then monthly thereafter over the remaining term to 10/03/2035. The RSU award vests 25% on the first anniversary and then in annual 25% installments thereafter. Following these transactions, the reporting person beneficially owns 9,031 option-derived shares and 3,625 RSUs, reported as direct ownership.